Galápagos NV (NASDAQ:GLPG) has earned an average rating of “Hold” from the twelve analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, four have given a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $115.17.
GLPG has been the subject of a number of research reports. BidaskClub cut shares of Galápagos from a “buy” rating to a “hold” rating in a research note on Friday, March 2nd. BTIG Research reissued a “buy” rating and set a $118.00 target price on shares of Galápagos in a research note on Thursday, February 8th. Zacks Investment Research upgraded shares of Galápagos from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Finally, ValuEngine upgraded shares of Galápagos from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd.
GLPG traded down $1.05 on Wednesday, reaching $91.73. The stock had a trading volume of 244,592 shares, compared to its average volume of 113,825. Galápagos has a 12-month low of $72.90 and a 12-month high of $121.09. The stock has a market capitalization of $4,921.63, a price-to-earnings ratio of -34.75 and a beta of 1.95.
Galápagos (NASDAQ:GLPG) last released its quarterly earnings data on Thursday, February 22nd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.02). Galápagos had a negative net margin of 74.70% and a negative return on equity of 12.08%. The firm had revenue of $58.37 million during the quarter, compared to analysts’ expectations of $42.84 million. analysts predict that Galápagos will post -4.28 earnings per share for the current year.
A number of institutional investors and hedge funds have recently bought and sold shares of GLPG. Financial Gravity Companies Inc. acquired a new position in Galápagos in the 4th quarter valued at about $104,000. Tower Research Capital LLC TRC boosted its holdings in Galápagos by 7,340.0% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,488 shares of the biotechnology company’s stock valued at $140,000 after purchasing an additional 1,468 shares during the last quarter. Envestnet Asset Management Inc. boosted its holdings in Galápagos by 156.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 1,742 shares of the biotechnology company’s stock valued at $177,000 after purchasing an additional 1,063 shares during the last quarter. Advisor Group Inc. boosted its holdings in Galápagos by 23.4% in the 4th quarter. Advisor Group Inc. now owns 3,492 shares of the biotechnology company’s stock valued at $327,000 after purchasing an additional 663 shares during the last quarter. Finally, Atria Investments LLC boosted its holdings in Galápagos by 23.0% in the 4th quarter. Atria Investments LLC now owns 3,609 shares of the biotechnology company’s stock valued at $338,000 after purchasing an additional 676 shares during the last quarter. Hedge funds and other institutional investors own 19.37% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Galápagos NV (GLPG) Receives Consensus Recommendation of “Hold” from Analysts” was posted by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are accessing this report on another website, it was illegally stolen and reposted in violation of US & international copyright and trademark laws. The legal version of this report can be accessed at https://www.thelincolnianonline.com/2018/05/18/galapagos-nv-glpg-receives-consensus-recommendation-of-hold-from-analysts.html.
Galápagos Company Profile
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
Receive News & Ratings for Galápagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galápagos and related companies with MarketBeat.com's FREE daily email newsletter.